Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2111MR)

This product GTTS-WQ2111MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2111MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ62MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ14974MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ15294MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ14737MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ3047MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ10828MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ2782MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ862MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.